Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481592 · ClinicalTrials.gov registry record · Phase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
A Phase 2 study of Endometrial Cancer, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 12
- Study locations
NCT06481592 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 60 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (89% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT06481592, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Conditions Studied
Interventions
- BIOLOGICAL Lifileucel
Study Locations (12)
Florida
- Orlando Health - Orlando
- H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa
Arizona
- Honor Health - Phoenix
California
- University of Southern California - Los Angeles
Georgia
- Augusta University - Augusta
Kentucky
- UofL Health - Brown Cancer Center - Louisville
Michigan
- Barbara Ann Karmanos Cancer Hospital - Detroit
New York
- Roswell Park Cancer Institute - Buffalo
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06481592
The ClinicalTrials.gov registry entry for NCT06481592 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lifileucel is the first listed.
NCT06481592 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06481592 about?
NCT06481592 is a clinical study titled "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.". The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
What is the current status of trial NCT06481592?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-10-29. Estimated completion is 2029-11.
What conditions does trial NCT06481592 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06481592?
The interventions under investigation include: Lifileucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06481592?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481592 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.